- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02480868
ARTEBONE Bone Void Filler in Arthrodesis Procedure of the Ankle
A Prospective Clinical Investigation to Assess Safety and Performance of ARTEBONE as Bone Void Filler in a Single Arthrodesis Procedure of the Ankle (Ankle Joint or Subtalar Joint)
Study Overview
Detailed Description
This is a multi-centre, prospective clinical investigation in subjects in need of a single arthrodesis procedure of the ankle (ankle joint or subtalar joint) to relieve persistent pain due to primary or secondary osteoarthritis.
The objectives of the study are to assess safety and performance of ARTEBONE as Bone Void Filler in the single arthrodesis procedure of the ankle (ankle joint or subtalar joint).
The study will be monitored regularly by Clinical Research Associates (CRAs). Monitoring procedures include one or more visits designed to clarify all prerequisites before the study commences. Interim monitoring visits will take place on a regular basis according to a schedule fixed by mutual agreement. During these visits, the CRA will check for completion of the entries on the Case Report Forms (CRFs), their compliance with the Clinical Investigation Plan (CIP), the standard operating procedures (SOP), Good Clinical Practice and International Organization for Standardization 14155 (ISO 14155), and will compare the CRF entries with the source data, as well as update the Investigator´s File (IF).
Source data verification will be performed in an unassisted way (direct access to source documents), unless otherwise required by the local ethics committee.
The sample size of 30 subjects was considered adequate for the safety and performance evaluation in this indication based on earlier discussions with the authorities.
An interim analyses will be performed for 6 months data. There will be descriptive analysis only and comparison to literature. Literature search has been done according to European Union (EU) guidelines.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Jyväskylä, Finland, 40620
- Central Hospital Of Central Finland
-
Lappeenranta, Finland, 53101
- South Karelia Central Hospital
-
Oulu, Finland, 90220
- Oulu University Hospital
-
Vantaa, Finland, 00029
- Helsinki University Central Hospital Peijas
-
-
-
-
-
Szczecin, Poland, 71252
- Autonomous Public Clinical Hospital No. 1 of Pomeranian Medical University in Szczecin named after professor Tadeusz Sokołowski
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient has signed the independent ethics committee approved informed consent form specific to this investigation prior to enrollment.
- The patient is diagnosed with primary or secondary osteoarthritis requiring fusion of the ankle joint (tibiotalar) or the subtalar joint.
- The fusion site should be able to be rigidly stabilized with two or three screws across the fusion site.
- The patient is independent, ambulatory, and could comply with all post-operative evaluations and visits.
- The patient is at least 18 years of age and considered to be skeletally mature.
Exclusion Criteria:
- The patient has undergone previous fusion surgery of the proposed fusion site.
- The fusion site requires other than screw fixation, more than three screws across the fusion site to achieve rigid fixation, or more than one kit (3 cc) of graft material.
- There is radiographic evidence of bone cysts, segmental defects or growth plate fracture around the fusion site that may negatively impact bony fusion.
- The patient currently has untreated malignant neoplasm(s) at the surgical site, or is currently undergoing radio- or chemotherapy.
- The patient has severe diabetes with neuropathy.
- The patient has a metabolic disorder known to adversely affect the skeleton, other than primary osteoporosis or diabetes (e.g., renal osteodystrophy or hypercalcemia).
- The patient uses chronic medications known to affect the skeleton (e.g., glucocorticoid usage > 10 mg/day).
- The patient uses immunosuppressive treatment or medication for osteoporosis.
- The patient has systemic or severe local inflammation or infections.
- The patient has a pre-fracture neuromuscular or musculoskeletal deficiency which might limit the ability to perform objective functional measurements.
- The patient is physically or mentally compromised (e.g., currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.) to the extent that the investigator judges the patient to be unable or unlikely to remain compliant.
- The patient has an allergy to reindeer protein.
- The patient has received an investigational therapy or approved therapy for investigational use within 30 days of surgery.
- The patient is a prisoner, known or suspected to be transient, or has a history of drug/alcohol abuse within the 12 months prior to screening for study entry.
- The patient is pregnant or a female intending to become pregnant during the study period.
- The patient is deemed morbidly obese (body mass index [BMI] > 45 kg/m2).
- The patient has a recent history of smoking during the past six months prior to screening for study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ARTEBONE
Bone Void Filler
|
4,3 g Bone Void Filler
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidence of unanticipated serious adverse device effects
Time Frame: Before or at 12 months
|
Before or at 12 months
|
|
Bone fusion rates
Time Frame: At 6 months (plus or minus 2 weeks)
|
Bone fusion rates assessed by sequential post-operative radiographs and Computer tomography at 6 months (both evaluated by two independent radiologists).
|
At 6 months (plus or minus 2 weeks)
|
Bone fusion rates
Time Frame: At 12 months (plus or minus 2 weeks)
|
Bone fusion rates assessed by sequential post-operative radiographs at 12 months (evaluated by two independent radiologists).
|
At 12 months (plus or minus 2 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: Within 12 months
|
Adverse events recorded either voluntarily by the subject in response to a non-leading question (i.e. "how have you been feeling?") or following a clinical observation. All adverse events will be assessed by the investigator according to their severity, relationship to the investigational product, action taken, and outcome status as defined in the ISO14155 guideline. |
Within 12 months
|
Time-points for returning to work
Time Frame: Within 12 months
|
Secondary performance endpoint
|
Within 12 months
|
Functional performance (Scores of American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Scale)
Time Frame: 6 months (plus or minus 2 weeks)
|
Functional performance at 6 months, secondary performance endpoint
|
6 months (plus or minus 2 weeks)
|
Functional performance (Scores of American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Scale)
Time Frame: 12 months (plus or minus 2 weeks)
|
Functional performance at 12 months, secondary performance endpoint
|
12 months (plus or minus 2 weeks)
|
Subjective pain evaluation (VAS) for fusion site and at weight bearing
Time Frame: 12 weeks (plus or minus 1 week)
|
Secondary performance endpoint
|
12 weeks (plus or minus 1 week)
|
Subjective pain evaluation (VAS) for fusion site and at weight bearing
Time Frame: 6 months (plus or minus 2 weeks)
|
Secondary performance endpoint
|
6 months (plus or minus 2 weeks)
|
Subjective pain evaluation (VAS) for fusion site and at weight bearing
Time Frame: 12 months (plus or minus 2 weeks)
|
Secondary performance endpoint
|
12 months (plus or minus 2 weeks)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Juhana Leppilahti, Professor, Oulu University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ARTEBONE 01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
University of California, San FranciscoStanford University; Robert Wood Johnson FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
Hospital for Special Surgery, New YorkRoyal Infirmary of EdinburghRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited States, United Kingdom
-
Ottawa Hospital Research InstituteNot yet recruitingKnee Osteoarthritis | Hip Osteoarthritis
-
University Hospital, LilleCompleted
-
Massachusetts General HospitalNewton-Wellesley Hospital; The New England Baptist HospitalCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
West Virginia UniversityAgency for Healthcare Research and Quality (AHRQ)WithdrawnKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
Diakonhjemmet HospitalThe Research Council of NorwayCompletedKnee Osteoarthritis | Hip OsteoarthritisNorway